spacer
spacer
spacer
spacer
No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)
Heje KB, Lindhardt MS, Meddis A, Knudsen A, Kronborg G, Weis N, Lebech A, Kirk O, HelWeg-Larsen J, Helms M, Fischer CP, Hansen AE, Møller S, Siebner HR, Hove JD, Gerstoft J and Benfield T2025
cccc